#1 Clinical Trials Search in Europe

Filgotinib

Filgotinib is an oral medication being studied in clinical trials for the treatment of various inflammatory conditions, including rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and juvenile idiopathic arthritis. These trials aim to evaluate the safety, effectiveness, and long-term outcomes of filgotinib in patients with these chronic inflammatory diseases. The studies range from pharmacokinetic assessments to large-scale observational studies in real-world settings, providing valuable insights into how filgotinib may benefit patients across different conditions and populations.

Table of Contents

Introduction

Filgotinib is a new medication being studied for the treatment of several inflammatory diseases. It is currently undergoing clinical trials to evaluate its effectiveness and safety in conditions like rheumatoid arthritis, ulcerative colitis, and juvenile idiopathic arthritis. This article will provide an overview of what is currently known about filgotinib based on ongoing research studies.

What is Filgotinib?

Filgotinib (also known by the brand name Jyseleca) is an oral medication that belongs to a class of drugs called JAK inhibitors[1]. It works by blocking certain enzymes in the body that are involved in inflammation. Filgotinib is being developed as a treatment option for various inflammatory and autoimmune conditions.

Other names for filgotinib include:[1]

  • GS-6034
  • GLPG0634

Conditions Treated with Filgotinib

Based on current clinical trials, filgotinib is being studied as a potential treatment for the following conditions:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting the joints[1]
  • Ulcerative Colitis (UC): An inflammatory bowel disease that causes inflammation and ulcers in the digestive tract[2][3]
  • Juvenile Idiopathic Arthritis (JIA): A type of arthritis that affects children and teenagers[4]

How Filgotinib Works

Filgotinib is a JAK inhibitor, which means it works by blocking enzymes called Janus kinases (JAKs). These enzymes play a role in the body’s immune response and inflammation processes. By inhibiting JAKs, filgotinib can help reduce inflammation and alleviate symptoms in conditions like rheumatoid arthritis and ulcerative colitis.

How Filgotinib is Administered

Filgotinib is taken orally in the form of tablets. In clinical trials, it has been administered in different ways:

  • As film-coated tablets taken once daily[2]
  • As mini-tablets for children and teenagers, which may be easier to swallow[4]

The dosage of filgotinib may vary depending on the condition being treated and the patient’s body weight. For example, in some studies, doses of 100 mg or 200 mg per day have been used for adults[2].

Effectiveness of Filgotinib

Clinical trials are ongoing to evaluate the effectiveness of filgotinib in various conditions. Some of the measures being used to assess its effectiveness include:

  • For Rheumatoid Arthritis: Improvement in joint symptoms and overall disease activity, measured by scales like the ACR response and DAS28(CRP) score[1]
  • For Ulcerative Colitis: Improvement in symptoms, disease remission, and quality of life[2][3]
  • For Juvenile Idiopathic Arthritis: Evaluation of how the drug is processed in children’s bodies (pharmacokinetics) and its effects on symptoms[4]

Researchers are also looking at how filgotinib affects patients’ quality of life and fatigue levels using questionnaires like the SF-36 and FACIT-Fatigue scale[1].

Safety and Side Effects

As with any medication, it’s important to understand the potential side effects and safety profile of filgotinib. Clinical trials are closely monitoring for any adverse events (side effects) that may occur during treatment. Some of the safety measures being evaluated include:

  • Number of participants experiencing treatment-emergent adverse events (TEAEs)[1]
  • Serious adverse events (SAEs)[3]
  • Side effects that may lead to discontinuation of the treatment[2]

It’s important to note that the full safety profile of filgotinib is still being established through ongoing research.

Ongoing Research

Several clinical trials are currently underway to further investigate filgotinib:

  • Long-term safety and effectiveness studies in rheumatoid arthritis patients[1]
  • Studies evaluating its use in ulcerative colitis, including how well it works and its safety in real-world settings[3]
  • Research on its use in children and teenagers with juvenile idiopathic arthritis[4]
  • Studies looking at how food affects the absorption of filgotinib and comparing different formulations (e.g., tablets vs. mini-tablets)[5]

Frequently Asked Questions

Is filgotinib approved for use?

Filgotinib’s approval status may vary by country and condition. It is currently approved in some regions for rheumatoid arthritis, but its use for other conditions like ulcerative colitis is still being studied. Always check with your healthcare provider for the most up-to-date information on its approval status in your area.

How long does it take for filgotinib to work?

The time it takes to see effects from filgotinib can vary depending on the condition being treated. In clinical trials, researchers are evaluating its effects at various time points, from as early as 10 weeks to up to 104 weeks (2 years) of treatment. Your doctor can provide more specific information based on your individual case.

Can filgotinib be used in children?

Research is ongoing to evaluate the use of filgotinib in children and teenagers with juvenile idiopathic arthritis. A specific formulation (mini-tablets) is being studied for easier administration in younger patients. However, its use in children is still experimental and not yet approved for general use.

Summary

Aspect Details
Drug Name Filgotinib (Jyseleca)
Drug Class JAK inhibitor
Conditions Studied Rheumatoid Arthritis, Ulcerative Colitis, Juvenile Idiopathic Arthritis
Administration Oral tablets or mini-tablets, once daily
Key Benefits Reduction in inflammation, improvement in disease symptoms and quality of life
Safety Monitoring Ongoing evaluation of adverse events and long-term safety
Research Status Multiple clinical trials in progress for various conditions and patient groups

Glossary

  • JAK inhibitor – A type of medication that blocks Janus kinase enzymes, which are involved in inflammation and immune responses
  • Rheumatoid Arthritis (RA) – A chronic inflammatory disorder that primarily affects the small joints of the hands and feet
  • Ulcerative Colitis (UC) – A type of inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum
  • Juvenile Idiopathic Arthritis (JIA) – A form of arthritis that affects children and teenagers, causing joint pain and inflammation
  • Pharmacokinetics – The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body
  • Adverse Event – Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure

Trial sources

  • [1]: https://clinicaltrials.gov/study/NCT02065700
  • [2]: https://clinicaltrials.gov/study/NCT02914522
  • [3]: https://clinicaltrials.gov/study/NCT05817942
  • [4]: https://clinicaltrials.gov/study/NCT06222034
  • [5]: https://clinicaltrials.gov/study/NCT06043739
Aspect Details
Drug Name Filgotinib (also known as GS-6034, GLPG0634, Jyseleca)
Conditions Studied Rheumatoid Arthritis, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis
Administration Oral tablets, typically once daily
Study Types Pharmacokinetic studies, long-term extension studies, observational studies in real-world settings
Key Outcome Measures Treatment persistence, clinical response/remission rates, disease activity scores, quality of life measures, safety assessments
Study Durations Range from short-term pharmacokinetic studies to long-term extensions up to 437 weeks
Special Populations Studies include adults and children (8 to <18 years), patients with hepatic impairment
Safety Monitoring Adverse events, serious adverse events, laboratory abnormalities

FAQ

  • What is filgotinib? Filgotinib is an oral medication being investigated for the treatment of inflammatory conditions like rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and juvenile idiopathic arthritis. It belongs to a class of drugs called JAK inhibitors that work by modulating the immune system.
  • What conditions is filgotinib being studied for in clinical trials? Clinical trials are evaluating filgotinib for several inflammatory conditions, including rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and juvenile idiopathic arthritis. These studies aim to assess its effectiveness and safety in treating these chronic inflammatory diseases.
  • How is filgotinib administered in clinical trials? In most clinical trials, filgotinib is administered as an oral tablet taken once daily. The dosage may vary depending on the specific study and condition being treated. Some trials are also evaluating different formulations, such as mini-tablets for pediatric patients.
  • What are some of the main outcomes being measured in filgotinib clinical trials? Key outcomes being measured include treatment persistence rates, clinical response and remission rates, changes in disease activity scores, quality of life improvements, and safety assessments such as the number of adverse events. Specific measures vary by condition but often include standardized assessment tools for each disease.
  • How long do filgotinib clinical trials typically last? The duration of filgotinib clinical trials varies widely. Some pharmacokinetic studies may last only a few days, while long-term extension studies can continue for several years (up to 437 weeks in one study). Observational studies in real-world settings often follow patients for 2-4 years to assess long-term outcomes and safety.

Ongoing Clinical Trials on Filgotinib

  • Study on Filgotinib and Triamcinolone for Newly Diagnosed Rheumatoid Arthritis Patients

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Effectiveness of Filgotinib for Patients with Refractory Behcet’s Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Long-term safety study of filgotinib tablets in adults with ulcerative colitis who completed previous filgotinib treatment

    Not recruiting

    3 1 1
    Investigated drugs:
    Hungary

  • Study on Rheumatoid Arthritis: Evaluating Methotrexate, Golimumab, and Hydroxychloroquine Sulfate for Patients with Autoantibodies and Response to Glucocorticoids

    Not recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Long-Term Safety and Effectiveness of Filgotinib for Patients with Rheumatoid Arthritis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Germany Hungary

  • Study on Filgotinib for Children and Teens with Juvenile Idiopathic Arthritis

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Poland Spain

  • Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Estonia France +9

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. This helps determine appropriate dosing and potential drug interactions.
  • JAK inhibitor: A class of medications that work by blocking Janus kinase (JAK) enzymes, which are involved in inflammation. Filgotinib belongs to this class of drugs.
  • Disease Activity Score (DAS28): A measure of disease activity in rheumatoid arthritis that takes into account the number of tender and swollen joints, as well as markers of inflammation in the blood.
  • American College of Rheumatology (ACR) response: A standardized measure of improvement in rheumatoid arthritis symptoms, with ACR20, ACR50, and ACR70 indicating 20%, 50%, and 70% improvement respectively in specified criteria.
  • Endoscopy/Bleeding/Stool Frequency (EBS) remission: A measure of disease improvement in ulcerative colitis that considers endoscopic findings, rectal bleeding, and stool frequency.
  • Psoriatic Arthritis Disease Activity Score (PASDAS): A composite measure of disease activity in psoriatic arthritis that includes joint assessments, patient-reported outcomes, and laboratory markers.
  • Health Assessment Questionnaire-Disability Index (HAQ-DI): A patient-reported outcome measure that assesses physical function and disability in arthritis and other rheumatic diseases.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.